Oncology

#Cancer #Cancer research #DDW Turning Science into Business Summit #Drug discovery #Immunotherapy #Oncology

This week in drug discovery (6-10 November) 

News round-up for 6-10 November by DDW Digital Content Editor Diana Spencer. With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again. Most… Read More

#News

T cell attacking cancer cell
#Cancer immunotherapy #Cancer research #Events #Immunotherapy #Oncology

Latest advances in immunotherapy from SITC 2023

The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (SITC 2023) took place on 1-5 November 2023, at San Diego Convention Center in San Diego, US. CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial… Read More

#Cancer Research #News #Trending News

Immunotherapy
#Antibody-based therapeutics #Cancer research #Immunotherapy #Oncology #T cell activation

Targeting advances in immunotherapies

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Christian Leisner, Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Why are existing immunotherapies restricted to certain patient populations?  CL:… Read More

#Cancer Research #Exclusive Content

Medical professional examining mammogram
#Breast cancer #Drug repurposing #Hormone therapy #MHRA #Oncology #UK

UK women to benefit from drug to prevent breast cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for anastrozole, to prevent breast cancer in post-menopausal women at moderate or high risk of developing the disease. The hormone treatment was already authorised for use in the treatment of breast cancer… Read More

#News #Trending News

Scientist in laboratory
#Cancer research #Cancer Research UK #Collaboration #KWF Dutch Cancer Society #Oncology

UK-Dutch alliance to strengthen early clinical oncology research

Cancer Research UK and the KWF Dutch Cancer Society (KWF) have announced a new multi-project strategic partnership to advance promising therapeutic agents for cancer. Under the partnership, KWF intends to provide funding to enable the development of select early phase clinical programmes through Cancer Research UK’s Centre… Read More

#Cancer Research #News

Non-small cell lung cancer
#Lung cancer #MHRA #Mirati Therapeutics #Non-small cell lung cancer (NSCLC) #Oncology #UK

MHRA approves drug for lung cancer with limited therapy options

The UK regulator has approved a new treatment for non-small cell lung cancer (NSCLC) in adults that has a mutation and produces a rare protein called KRAS G12C. The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Krazati (adagrasib) to treat patients whose disease is… Read More

#News #Regulatory

Cancer cells
#Cancer research #Immunotherapy #Nimbus #Oncology #Phase I trial #Solid tumours

HPK1 inhibitor demonstrates clinical benefit in solid tumours

Initial data from an ongoing Phase I/II study of HPK1 inhibitor NDI-101150 show clinical benefit in three patients with solid tumours, including one complete response in a patient with renal cell carcinoma. Two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> six… Read More

#Cancer Research #News

#Cancer research #DDW Turning Science into Business Summit #Immunotherapy #Oncology #Webinar

Have you registered for DDW’s Cancer Research Summit?

Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM… Read More

#Cancer Research #News

Cancer immunotherapy
#Cancer immunotherapy #Drug discovery #eBook #Immunotherapy #Oncology #Precision medicine

Where are the latest breakthroughs in immunotherapy?

The latest in the DDW eBook series ‘Immunotherapy: Where are the advances and breakthroughs?‘ is now available for download. This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer… Read More

#News

Immunotherapy eBook
#Cancer immunotherapy #Drug discovery #eBook #Immunotherapy #Oncology #Precision medicine

Immunotherapy: Where are the advances and breakthroughs?

This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer care: Where are the advances in treatments for triple-negative breast cancer? Drug development: Five years of oncology developments Why immunotherapy is here… Read More

#DDW eBooks #Intelligence

ESMO 2023
#Cancer research #Clinical trials #ESMO #Oncology

Breaking clinical trial news from ESMO 2023

The European Society for Medical Oncology Meeting (ESMO) 2023 took place from 20-24 October in Madrid, Spain. Many drug discovery companies took the opportunity to share their latest cancer research findings. Axicabtagene ciloleucel, Kite Two indirect comparative analyses of CAR T-cell therapy axicabtagene ciloleucel vs. bispecific… Read More

#Cancer Research #News #Trending News

Biomarkers concept
#Antibody-based therapeutics #Biomarkers #Cancer research #DDW Turning Science into Business Summit #Oncology

DDW Cancer Summit: Master biomarker-driven approaches

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will take place online on 16 November at 7AM PDT / 10AM EDT / 3PM GMT / 4PM CET and will be available on-demand after that date. The free… Read More

#News

Blood cancer
#Bispecific Antibodies #Cancer research #Haematology #MHRA #Oncology #UK

New UK therapy option for hard-to-treat lymphoma

The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The conditional marketing authorisation for Great Britain is based on the single-arm Phase… Read More

#News #Regulatory

Cancer research
#Cancer research #Kura Oncology #Oncology #Phase I trial #Solid tumours

Farnesyl transferase inhibitor for solid tumours enters trials

Kura Oncology’s FIT-001 Phase I dose-escalation trial of KO-2806, a farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumours, has commenced with the dosing of the first patient. FIT-001 is a first-in-human, multicentre, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary… Read More

#Cancer Research #News

Cancer research
#Cancer research #DDW Turning Science into Business Summit #Immunotherapy #Oncology #Webinar

Expert line-up for DDW’s Cancer Research Summit

Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM PST /… Read More

#Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Cancer research #Iksuda Therapeutics #Oncology #Phase I trial #Solid tumours

First patient dosed with antibody drug conjugate for HER2+ tumours

Iksuda Therapeutics has dosed the first patient in a Phase I trial of antibody drug conjugate (ADC) IKS014 in patients with advanced solid tumours that express HER2. This follows positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through… Read More

#Cancer Research #News